Warner-Lambert GMP Conviction Plays Role In Neurontin Case
Executive Summary
Warner-Lambert's 1995 guilty plea related to good manufacturing practices compliance is an important factor in the Neurontin off-label promotion case settled by Pfizer on May 13
You may also be interested in...
US FDA Learns 'Lessons Of History,' Takes Opioid Fight To Gabapentinoids
Agency investigating potential misuse and abuse of gabapentinoids, which CDC had recommended as alternative to opioids, in latest twist to epidemic.
Third-Party Payers Denied Class Certification in Neurontin, Vioxx Litigation
Third-party payers may have a tough time getting class certification in suits alleging economic injury from drug purchases given recent rulings in Neurontin and Vioxx litigation
Third-Party Payers Denied Class Certification in Neurontin, Vioxx Litigation
Third-party payers may have a tough time getting class certification in suits alleging economic injury from drug purchases given recent rulings in Neurontin and Vioxx litigation